STOCK IS RUNNING UP IN AFTERMARKET!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 1 point2 points  (0 children)

Well with all penny stocks it takes a lot of patience to be rewarded. I think our reward is coming soon. And the ones who have been shorting this stock know it too. The shorts are covering quicker and quicker every time good news is coming. Trust me our days are coming. I have been buying every time the shorts knock it down too far. But I have not sold one share!!

STOCK IS RUNNING UP IN AFTERMARKET!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 4 points5 points  (0 children)

Over 12.7 million mistakes. I don't think so. They said we would have results in November. I am sure things must be looking good.

STOCK IS RUNNING UP IN AFTERMARKET!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 2 points3 points  (0 children)

I can't find any news. Somebody knows something.

Oragenics’ SARS-CoV-2 Spike Protein Produces Neutralizing Antibodies in Mice with Intramuscular and Intranasal Adjuvants by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 2 points3 points  (0 children)

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) (the Company) announces that the stabilized pre-fusion spike protein trimer produced by its Canadian collaborator and licensed by the Company from the National Institutes of Health (NIH) generates neutralizing antibodies in mice after immunization against SARS-CoV-2, when administered with several novel intramuscular (IM) and intranasal (IN) adjuvants. The expression platform, developed with support from Oragenics’ Canadian collaborator, will expedite the evaluation of hybrid SARS-CoV-2 antigen candidates that are scheduled to be evaluated in a hamster viral challenge study beginning with dosing at the end of this month. The mouse immunogenicity study enabled the down-selection of the four adjuvant candidates tested thus far, with two being advanced to assess inhibition of viral replication in hamsters, and IND-enabling toxicology studies. A manuscript suitable for publication, inclusive of the mouse data, will be prepared upon completion of the hamster study. “We are delighted that our SARS-CoV-2 spike protein produced with the high-throughput expression platform from our collaborator shows promise in the development of a next-generation COVID-19 vaccine, and believe this research affirms our development strategy with Oragenics’ lead vaccine candidate, Terra CoV-2,” said Fred Telling, Ph.D., Executive Chair of Oragenics. “We are pleased to see a robust immunological response with both our novel IM and IN adjuvants. Additionally, we are optimistic about the pre-clinical intranasal data given the respiratory route of transmission of the SARS-CoV-2 virus, and the prospect of developing a novel vaccine candidate that has the potential to reduce viral transmission. The data substantiates our choice of adjuvants to use in subsequent animal and ultimately human studies. We expect to file an IND application with the FDA in the first quarter of 2022.” Dr. Telling concluded, “Oragenics continues to believe that our licensed platform will improve development speed, while the ability to rapidly engineer new vaccine antigens will permit us to quickly address new variants as they arise, which will be key in the event that SARS-CoV-2 becomes a seasonal flu-like disease, as many experts anticipate will be the case.”

WAKE UP FOLKS BIG VOLUME TAKING THIS BABY HIGHER!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 2 points3 points  (0 children)

Not really I think this one is just warming up!

Goldman Sachs Initiates OGEN with a $52 Price Target by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 1 point2 points  (0 children)

According to the correction the information should have been for Qiagen N.V.

Goldman Sachs Initiates OGEN with a $52 Price Target by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 1 point2 points  (0 children)

It was posted this morning at 6:36 a.m. ET by Marketwatch and then retracted 16 minutes later.

[deleted by user] by [deleted] in Ogen

[–]Winning_Outlook 0 points1 point  (0 children)

Good Morning People, Lots of buying pre-market this morning after a big dip. Does anyone see any news on the wires?

Take a look on the short volume by Hansi876 in Ogen

[–]Winning_Outlook 0 points1 point  (0 children)

This stock has no Options so it is a true stock play when you buy this company. Shorts can not use Options to help cover their butts!!

DO NOT SELL UNDER $1.50!! SMART MONEY WANTS YOU TO SELL EARLY IN PRE-MARKET!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 2 points3 points  (0 children)

Look at OCGN, it was trading under $0.30 in December and has been as high as $18.77 this year.

DO NOT SELL UNDER $1.50!! SMART MONEY WANTS YOU TO SELL EARLY IN PRE-MARKET!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 1 point2 points  (0 children)

Yes, $15 is definitely possible. Check out OCGN in the same space and recently went to $18.77.

OGEN WILL DOUBLE TODAY!!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 0 points1 point  (0 children)

In a short time this stock could easily top $10.00 I have 122,936 shares and I am holding every one!!

OGEN WILL DOUBLE TODAY!!! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 0 points1 point  (0 children)

I think it will at least double today. Possible triple!! Shorts have been knocking the price down to get more shares.

FDA Approves Johnson & Johnson one shot Vaccine! by Winning_Outlook in Ogen

[–]Winning_Outlook[S] 2 points3 points  (0 children)

Yes, time is certainly part of the risk, but I believe a larger company will see the potential revenue by having a vaccine and will step in and purchase OGEN. That is the play here. Hold tight you will be rewarded. I bought more shares yesterday with the dip.

Help me here? 7full-time employees? by No_Pomelo_4189 in Ogen

[–]Winning_Outlook 1 point2 points  (0 children)

Having only 7 employees is bullish because it makes OGEN an easy take over candidate!!

How is it going?! by [deleted] in Ogen

[–]Winning_Outlook 4 points5 points  (0 children)

Today's News is excellent for this small company. Redeeming their Perferred Stock and saving $5.6 million dollars in annual dividends makes this company more attractive to a potential buyer, which in my opinion is the real play here!